AlphaYouOCUL: Kaiser Peter discloses a sale
By AlphaYouPublished Form 4
Kaiser Peter
Reporting filer
Kaiser Peter reported Sale in OCULAR THERAPEUTIX, INC: 9990 units of Common Stock, dated 2026-10-02. The full Form 4 contains 1 transaction entry.
- Disclosed
- Oct 6, 2026
Reported details
1 entry| Security | Owner | Date | Code | Action | Quantity | Price | Following holdings | Reporting delay | Filed terms and references |
|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Kaiser Peter | 2026-10-02 | S | Sale | 9990 | 7.05 | 254,388 | 4 days | Filed terms
|
Common Stock
- Owner
- Kaiser Peter
- Date
- 2026-10-02
- Code
- S
- Action
- Sale
- Quantity
- 9990
- Price
- 7.05
- Following holdings
- 254,388
- Reporting delay
- 4 days
- Filed terms and references
Filed terms
- security Title: Common Stock
- transaction Date: 2026-10-02
- deemed Execution Date:
- transaction Form Type: 4
- transaction Code: S
- equity Swap Involved: 0
- id: F1
- transaction Timeliness:
- transaction Shares: 9990
- id: F1
- transaction Price Per Share: 7.05
- id: F2
- transaction Acquired Disposed Code: D
- shares Owned Following Transaction: 254388
- direct Or Indirect Ownership: D
Purchases, sales, grants and option exercises are different transactions. The reported code identifies the action; it does not establish a motive.
Filing context
- Quantities and prices are shown in the units filed. No trade value is inferred from their product.
- Kaiser Peter: Chief Development Officer.
- The filing reports a Rule 10b5-1 trading plan.
- F1: Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on April 9, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on October 1, 2026. The sales do not represent a discretionary trade by the reporting person.
- F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.9900 to $7.1954, inclusive. The reporting person undertakes to provide to the Corporation, any security holder of the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
Original sources
Prepared automatically from public filing data. Report a correction.